Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Why Investors Should Add CBD and Biotech Stocks to their Portfolio

Livemoney January 12, 2021

Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative

Business Wire January 12, 2021

Pandemic Cases in the U.S. Are Now At Dangerous All-Time Highs

Livemoney January 11, 2021

Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy

Business Wire January 7, 2021

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

PR Newswire January 7, 2021

Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy

PR Newswire January 6, 2021

The New Strain of Virus Reportedly Hit New York

Livemoney January 6, 2021

Some of the Top Pharmaceutical Companies to Watch in New Year 2021

Livemoney January 6, 2021

Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference

Business Wire January 5, 2021

US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

Business Wire January 4, 2021

LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA

Business Wire December 28, 2020

Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health

GlobeNewswire December 28, 2020

Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

Business Wire December 23, 2020

Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts

Business Wire December 22, 2020

Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine

Business Wire December 21, 2020

Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine

Business Wire December 21, 2020

Dow Rockets on Stimulus Optimism

Livemoney December 15, 2020

U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older

Business Wire December 12, 2020

Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19

Business Wire December 11, 2020

BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

PR Newswire December 11, 2020